Molina Healthcare

WE WIN Together Week 2024 Brings Visionary Leaders to St. Louis Focusing on Community Engagement and Social Justice

Retrieved on:

星期一, 四月 15, 2024

Well, Public security, Health Promotion International, Equity, CNN Heroes, Learning, Social change, Molina Healthcare, CNN, Greater St. Louis, WIN Television, Community, WWTW, Social justice, Division, Knowledge, Management

ST. LOUIS, April 15, 2024 (GLOBE NEWSWIRE) -- WE WIN Together Week (WWTW) 2024 is set to make a significant impact in St. Louis, Missouri, from April 22-25. Hosted by WIN Network, Communities RISE Together, and Well-being and Equity in the World, this annual event, themed Being Better Ancestors in Turbulent Times, is more than just a gathering of influential voices; it's a celebration of community, learning, impact, and engagement.

Key Points:

ST. LOUIS, April 15, 2024 (GLOBE NEWSWIRE) -- WE WIN Together Week (WWTW) 2024 is set to make a significant impact in St. Louis, Missouri, from April 22-25.
The decision to host WWTW 2024 in St. Louis was intentional.
As WWTW 2024 approaches, excitement is building within St. Louis and among attendees from across the globe.
This year's event promises to be a transformative experience, uniting changemakers in a shared vision of equity, inclusion, and social justice.

Cardio Diagnostics Announces Publication of Study Showing That its PrecisionCHD™ Test Could Save Health Insurers Over $113 Million Annually

Retrieved on:

星期一, 四月 29, 2024

PrecisionCHD is an AI-powered multiomic DNA test using epigenetic and genetic biomarkers to aid in the detection of stable CHD.

Key Points:

PrecisionCHD is an AI-powered multiomic DNA test using epigenetic and genetic biomarkers to aid in the detection of stable CHD.
The model considered factors such as the number of tests performed, the cost of each test, and the impact of test results on treatment decisions.
The results suggest that using PrecisionCHD could lead to significant cost savings for payers, with an estimated $113.6 million saved per year for a plan with one million members.
These tools support targeted, data-driven decisions in CHD treatment and management, potentially revolutionizing approaches to healthcare delivery and cost management.

Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China

Retrieved on:

星期四, 四月 11, 2024

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced results from a Phase 3 study evaluating the efficacy and safety of AJOVY for the prevention of migraine in adult Chinese patients.

Key Points:

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced results from a Phase 3 study evaluating the efficacy and safety of AJOVY for the prevention of migraine in adult Chinese patients.
In the study, AJOVY achieved primary endpoint and all secondary endpoints, significantly reducing the number of migraine days experienced per month, demonstrating superior efficacy over placebo.
Study data also show AJOVY was safe and well tolerated with no emerging safety signals.
Additional findings from this study are planned for presentation at a medical meeting later this year.

Molina Healthcare Wins Michigan Medicaid Contract

Retrieved on:

星期四, 四月 11, 2024

Health, State, Local, Public Policy, Government, Managed Care, Health Insurance, Molina Healthcare, MDHHS, Health care, Medicaid

Molina Healthcare, Inc. (NYSE: MOH) (“Molina” or the “Company”) announced today that the Michigan Department of Health and Human Services (MDHHS) intends to award a Comprehensive Health Care Program contract to Molina’s health plan subsidiary, Molina Healthcare of Michigan.

Key Points:

Molina Healthcare, Inc. (NYSE: MOH) (“Molina” or the “Company”) announced today that the Michigan Department of Health and Human Services (MDHHS) intends to award a Comprehensive Health Care Program contract to Molina’s health plan subsidiary, Molina Healthcare of Michigan.
Molina confirmed it was awarded the contract in six service regions.
The go-live date for Molina Healthcare of Michigan’s new Medicaid contract is expected to be October 1, 2024.
Molina Healthcare of Michigan will be one of nine health plans offering health care coverage to Michigan’s nearly 2 million total Medicaid beneficiaries.

Mayo Clinic Diet Survey Spotlights Important Correlation Between Weight Loss Medication and Behavioral Support Programs

Retrieved on:

星期二, 四月 23, 2024

ROCHESTER, Minn., April 23, 2024 /PRNewswire/ -- In a recent survey conducted by the Mayo Clinic Diet, a staggering 59% of respondents identified not finding the right weight loss program as the primary barrier to shedding pounds effectively. This revelation, coupled with the increasing use of weight loss medications like Ozempic alone, without physician guidance or comprehensive lifestyle program, has sparked concerns among experts.

Key Points:

The Mayo Clinic Diet survey, which polled 13,013 adults actively seeking or using weight-loss medications, underscores the pressing need for a more comprehensive and holistic approach to weight management.
The findings from the Mayo Clinic Diet survey serve as a wake-up call for both healthcare providers and individuals seeking effective weight loss solutions.
The Mayo Clinic Diet for Weight-Loss Medication has a number of new features and benefits including:
A 24-week support program tailored for members taking weight-loss medications.
One Mayo Clinic Diet member, Donna Cooper, commented on the combined success of her weight loss along with improved health markers.

Inaugural 'Korea Medical Innovation Research Forum' regular seminar, a success

Retrieved on:

星期五, 四月 19, 2024

To be registered as an official research organization by the National Assembly Secretariat... Expected to become Korea's leading medical think tank

Key Points:

To be registered as an official research organization by the National Assembly Secretariat... Expected to become Korea's leading medical think tank
Establishing a future medical system centered around prevention and management...
Expanding digital medical services
SEOUL, South Korea, April 19, 2024 /PRNewswire/ -- Amid growing concerns about a medical crisis as a result of acute conflict between the government and the medical community due to an increase in the quota of medical school admission, the regular seminar of the Korea Medical Innovation Research Forum (KMIRF) kicked off; experts from various fields of the medical field gathered to prepare for future medical reform.
Medical experts who serve as steering and working committee members of each division, including co-representatives Dae Hee Kang and Jong Yoon Lim, gathered and led a heated discussion for medical reform.
"We plan to hold regular seminars for KMIRF at least six times a year and frequently put forward future medical innovation policies with the cooperation of experts and policymakers in each field."

Breakthrough whole genome report for embryos created during IVF delivers 100x data for parents, peer reviewed validation published

Retrieved on:

星期一, 四月 15, 2024

Risk, Pregnancy, Birth, WGS, Parent, IVF, Genetics, DNA, DSM-IV codes, Harvard Medical School, Genome, Multimedia, Molina Healthcare, Cancer, SAN, Interest, Vaccine

Orchid published its clinical validation of whole genome embryo screening, a step forward in IVF and genetic screening.

Key Points:

Orchid published its clinical validation of whole genome embryo screening, a step forward in IVF and genetic screening.
Until now, standard genetic screening for embryos read less than 1% of an embryo's genome, which left most conditions undetected until pregnancy, birth, or even through childhood into adulthood.
Then, it could take years to accurately diagnose these conditions, causing harm, stress, and cost to impacted individuals and their families.
Now, Orchid have proven their ability to use whole-genome sequencing (WGS) to successfully read >99% of an embryo's genome, providing 100x more data than traditional tests.

Global Experts from SEPA Call for the Control of Gingivitis Rather than Waiting for Periodontitis to Develop

Retrieved on:

星期一, 四月 8, 2024

SEPA: Limited knowledge among oral health teams of the recommendations and evidence currently available on oral antiseptics (that are clinically proven to be effective) reduces their implementation; therefore, more practical and simple advice is proposed.

Key Points:

This was highlighted at an International Summit of Experts held at the Casa de las Encías in Madrid, Spain, the headquarters of the SEPA Foundation.
"Periodontal diseases are prevalent worldwide, affecting hundreds of millions of people," says the meeting coordinator, Dr. Paula Matesanz, vice president of SEPA.
As Dr. Iain Chapple summarizes, "It is time for a paradigm shift: we must control gingivitis and not wait until periodontitis develops."
J Clin Periodontol 2022 Jun:49 Suppl 24:4-71 (version adapted by SEPA available at https://portal.guiasalud.es/gpc/tratamiento-periodontitis-estadio-iv )
* Chapple I, Time to take gum disease seriously.

Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity

Retrieved on:

星期日, 四月 7, 2024

ANN ARBOR, Mich., April 07, 2024 (GLOBE NEWSWIRE) -- Esperion (Nasdaq: ESPR) today announced the presentation of results from three pre-specified subgroups from CLEAR Outcomes at the 2024 American College of Cardiology’s Annual Scientific Sessions (ACC.24): women, Hispanic/Latinx, and patients with obesity. These results align with the American College of Cardiology’s robust diversity, equity and inclusion programs to drive cultural change across the profession and ensure that the cardiovascular care team is as diverse as the patients they care for and that all patients are represented in cardiovascular research. The data also reinforce the mission of the ACC: transforming cardiovascular care for all.

Key Points:

“Bempedoic acid is the only FDA approved non-statin LDL lowering therapy to demonstrate reductions in MACE in both primary prevention and secondary prevention patient populations.
The Hispanic population is the largest ethnic minority in the U.S., yet is a population historically underrepresented in clinical trials.
At Esperion, we discover, develop, and commercialize innovative medicines to help improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases.
CLEAR Outcomes is part of the CLEAR clinical research program for NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet.

The Oncology Institute and Healthly Forge Strategic Alliance to Elevate Cancer Care Access to Healthly Patients Across Southern California

Retrieved on:

星期四, 四月 4, 2024

Partnership, Patient, Molina Healthcare, Physician

Commencing July 1, 2024, TOI will offer its cancer care services to patients affiliated with Healthly’s medical groups and associated physicians across the region.

Key Points:

Commencing July 1, 2024, TOI will offer its cancer care services to patients affiliated with Healthly’s medical groups and associated physicians across the region.
Leveraging TOI’s extensive network of oncology clinics and providers, this partnership aims to deliver convenient and comprehensive cancer care services to patients within the Healthly network.
“Navigating cancer is a multifaceted challenge, often representing one of the most trying periods in a patient’s life.
Through this strategic partnership, we aim to offer innovative care pathways, including access to clinical trials, to enhance patient access to cutting-edge drugs and treatments at reduced costs.”